Abstract:Cytochrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug reactions. P450s display broad substrate reactivity, and prediction of metabolites is complex. QM/MM studies of P450 reactivity have provided insight into important details of the reaction mechanisms and have the potential to make predictions of metabolite formation. Here we present a comprehensive study of the oxidation of three widely used pharmaceutical compounds (S-ibuprofen, diclofenac, and S-warfarin) by one of the major drug-metabolizing P450 isoforms, CYP2C9. The reaction barriers to substrate oxidation by the iron-oxo species (Compound I) have been calculated at the B3LYP-D/CHARMM27 level for different possible metabolism sites for each drug, on multiple pathways. In the cases of ibuprofen and warfarin, the process with the lowest activation energy is consistent with the experimentally preferred metabolite. For diclofenac, the pathway leading to the experimentally observed metabolite is not the one with the lowest activation energy. This apparent inconsistency with experiment might be explained by the two very different binding modes involved in oxidation at the two competing positions. The carboxylate of diclofenac interacts strongly with the CYP2C9 Arg108 side chain in the transition state for formation of the observed metabolite-but not in that for the competing pathway. We compare reaction barriers calculated both in the presence and in the absence of the protein and observe a marked improvement in selectivity prediction ability upon inclusion of the protein for all of the substrates studied. The barriers calculated with the protein are generally higher than those calculated in the gas phase. This suggests that active-site residues surrounding the substrate play an important role in controlling selectivity in CYP2C9. The results show that inclusion of sampling (particularly) and dispersion effects is important in making accurate predictions of drug metabolism selectivity of P450s using QM/MM methods.

Theoretical Studies on the Substrate Binding Mode and Regioselectivity of Human Cyp2c9 with S- and R-Warfarin

Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism.

Interactions of CYP2C9 with Different Substrates and Its Implications for Metabolic Mechanism

Kinetic Study of Cytochrome P450 3A4 Activity on Warfarin by Capillary Electrophoresis with Fluorescence Detection

Three-Dimensional Quantitative Structure Activity Relationship for Cyp2d6 Substrates

Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9

Negatively Cooperative Binding Properties of Human Cytochrome P450 2E1 with Monocyclic Substrates

Molecular determinant of substrate binding and specificity of cytochrome P450 2J2

Molecular Modeling of Human Cytochrome P450 2W1 and Its Interactions with Substrates.

New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

Exploring coumarin egress channels in human cytochrome P450 2A6 by random acceleration and steered molecular dynamics simulations.

Investigation on drug-binding in heme pocket of CYP2C19 with UV-visible and resonance Raman spectroscopies

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

Molecular dynamics simulations of CYP2E1.

Identification of New Substrates and Inhibitors of Human CYP2A7

An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62

Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F-F' Loop Perturbations

Identification and Enzymatic Activity Evaluation of a Novel <i>CYP2C9</i> Allelic Variant Discovered in a Patient

Structural and dynamic basis of human cytochrome P450 7B1: a survey of substrate selectivity and major active site access channels

Probing Ligand Binding Modes of Human Cytochrome P450 2J2 by Homology Modeling, Molecular Dynamics Simulation, and Flexible Molecular Docking

Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant